

Streamlining Cell Line Development: Strategies for Emerging Biotech Start-Ups

Thursday, May 26 | Cambridge, UK

Agenda

Start	End	Topic	Speaker
(Time Zone: BST)			
4:30 p.m.	5:00 p.m.	Registration	N/A
5:00 p.m.	5:10 p.m.	Welcome Address	
5:10 p.m.	6:00 p.m.	CHO Me the Way Fundamentals of Cell Line Development	Dr. Yash Patel (Sartorius)
6:00 p.m.	6:10 p.m.	Break Meet the Speaker	N/A
6:10 p.m.	6:50 p.m.	Ready Steady CHO Panel Discussion	Dr. Nicole Wakes (Abzena), Dr. Kerensa Klottrup-Rees (AstraZeneca), Dr. Holly Corrigan (GSK), Dr. Yash Patel (Sartorius)
6:50 p.m.	8:00 p.m.	Treat CHOself Cocktail Hour and Networking	N/A

Speakers



Dr. Yash Patel is a Product Specialist in Cell Line Development at Sartorius since August 2021. He has 11 years of experience in CHO cell line development and engineering, with a PhD from Prof. David James group at The University of Sheffield in collaboration with AstraZeneca. Dr. Patel's experience also encompasses time outside of academia during his employment with Lonza.



Dr. Nicole Wakes is the Senior Director of Cell Line Development at Abzena (Cambridge) Ltd, responsible for the technical and resource management of the cell line development group. She is an expert in CLD with more than 25 years of experience in the generation of cell lines for small and large molecule development. Nicole has been responsible for the generation of cell lines for a variety of biotherapeutic molecules from standard antibodies, antibody fragments, fusions, biosimilars and more novel biotherapeutic modalities.



Dr. Kerensa Klottrup-Rees is an Associate Principal Scientist at AstraZeneca, Cambridge UK within the cell line development team. She specialises in lab automation and has an interest in the use of large data sets to improve timely decision making. Previously Kerensa worked in the Gaithersburg USA site of AstraZeneca, and for Genetix on the development of the ClonePix FL for clonal cell line isolation. Her love of data in action came early on in her career from roles in Defence Science and Ordnance Survey seeing how the right tools and understanding of the power and limits of data could bring patterns to life.



Dr. Holly Corrigan received her PhD from the University of Aberdeen where she investigated the molecular response of eukaryote ribosomes to translational pausing. Holly joined the Cell Line Development team within the Biopharm Process Research department at GlaxoSmithKline (GSK) four years ago and now leads the Cell Line Engineering team which supports the generation of commercial cell lines for GSK's biopharmaceutical portfolio.